Gyros AB announced its selection as the 2011 winner of the SwedenBIO award. The award scheme, now in its fifth year, focuses attention on Swedish life science companies or industry leaders that have achieved significant national and international recognition during the previous year.
During 2010, Gyros saw major biopharmaceutical companies on both sides of the Atlantic continue to demonstrate their confidence in the Company’s nanoliter-scale immunoassay platform. Of particular significance was an increased market penetration in North America, the region containing many of the key players involved in global efforts to develop novel biotherapeutics. The number of service providers, such as CRO’s, implementing Gyrolab workstations into their projects lso increased. Having established the platform in the USA and Europe, Gyros is now focused on building awareness in Asia Pacific, where the Company has been appointing a network of distributors.
SwedenBIO is a private, non-profit organization whose mission is to enhance the visibility of the life science industry within Sweden and thereby improve conditions for its 190 member companies and support a successful, thriving community. Peter Honeth, State Secretary at the Swedish Ministry of Education and Research, presented the award to Gyros president and CEO, Erik Walldén, during the SwedenBIO annual meeting held at the the Royal Swedish Academy of Engineering Sciences in Stockholm on 25th May.
Commenting on the award, Erik Walldén, President and Chief Executive Officer of Gyros AB, said: “We are delighted to receive this award. Our growing, international installed base confirms that our unique platform, developed and manufactured in Sweden, is increasingly regarded as an established technology for bioanalysis during the development of biotherapeutics. Moving forward, Gyros is in an excellent position to set the industry standard for transforming the performance of immunoassays wherever they are utilized within the biopharmaceutical industry.”
The Company’s open, automated platform supports time-critical workflows in the biopharmaceutical industry, boosting productivity and cutting time to result. Automatically running immunoassays at nanoliter scale not only ensures faster development times, but also saves labor, sample and reagents. Assays are readily transferred downstream into GxP environments and between different sites, greatly facilitating collaborations between biopharmaceutical companies and their service providers.
Source: Gyros AB